Two-Step Immunotherapy Attacks Advanced Ovarian Cancer, Penn Medicine Researchers Report


February 4, 2013

Most ovarian cancer patients are diagnosed with late stage disease that is unresponsive to existing therapies. In a new study, researchers from the Perelman School of Medicine at the University of Pennsylvania School of Medicine show that a two-step personalized immunotherapy treatment – a dendritic cell vaccine using patients’ own tumor followed by adoptive T cell therapy – triggers anti-tumor immune responses in these type of patients. Four of the six patients treated in the trial responded to the therapy, the investigators report this month in OncoImmunology. The study was led by Lana Kandalaft, PharmD, MTR, PhD, research assistant professor of Obstetrics and Gynecology and director of clinical development in the Ovarian Cancer Research Center.

Penn Medicine News Release